Description

Cultrex®StemCellQualifiedHumanFibronectin,Pathclear®ispurifiedfromhumanplasmaandisPathclear®certifiedtobefreeofcommonpathogens.Fibronectinisanextracellularmatrixproteinthatisfoundabundantlyinbloodandconnectivetissues.Thesematricesareassociatedwiththeepithelialtomesenchymaltransitionofmetastaticcells,includingtumorcellswithstemcell-likeproperties.Fibronectinperformsessentialfunctionsincollagenfibrillogenesis,aseitherageneralcelladhesionmoleculeoramodulatorinbindingbetweencellsurfacesandtheextracellularmatrix.Fibronectinmatrixassemblyisessentialfornormalvertebratedevelopmentandapparentlycontributestothegenerationoftumormetastasesbysupportingtheestablishmentandpersistenceofpre-metastaticniches.Fibronectinissecretedasadisulfide-linkeddimerof230-270kDa,comprisedofthreetypesofrepeatingmodulesthatmediateinteractionswithextracellularmatrixcomponents(includingfibronectinitself),andcellsviaintegrinsandotherfibronectinreceptors.Thus,fibronectincanbeusedforcoatingtissueculturesurfacesorasamediumadditivetopromotecelladhesionandproliferation;itis0.2μmsterilefiltered.

Cultrex®StemCellQualifiedHumanFibronectin,Pathclear®isapurifiedplasmaextracellularmatrix proteinthathasbeendeveloped,producedandqualifiedspecifically toprovideafunctionallydefinedandeffectivefeeder-freesurfacefortheattachmentandmaintenanceofembryonicstemcellsinapluripotentstate

Qualitycontrolspecifications:

• PathClear®–testednegativeforeighthumanpathogenicvirusesincludingHepatitisA,BandC,HIV1and2,Hantaan,Seoul,andSinNombrebyPCR.
• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
• Endotoxinconcentration≤20EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
• Proteinconcentrationof1mg/ml.
• NomycoplasmacontaminationdetectedbyPCR.
• Providedin100mMCAPS,150mMNaCl,1mMCaCI2,pH11.5.
• Purity ≥90%(SDS-PAGE).
• BIOLOGicalactivitydeterminedforeachlot:
  • PromotestheattachmentofhumaniPSCs.
  • EffectivelymaintainshumaniPSCsinapluripotentstateinafeeder-freeculture.

SafetyStatement:

AlthoughCultrex®StemCellQualifiedHumanFibronectin,PathClear®hasbeentestedforthevirusesaboveitcontainshumansourcematerialandthereforeshouldbetreatedaspotentiallyinfectiousandhandledattheBiologicalSafetyLevel2tominimizeexposure.

Trevigen，Inc.是一家发展迅速的生物技术公司，致力于开发用于癌症研究，药物发现，遗传毒理学，再生医学和干细胞研究的产品和技术。我们提供试剂盒和试剂，用于研究DNA损伤和修复，细胞凋亡，氧化应激，癌细胞行为，3D培养和干细胞。该公司获得了美国国立卫生研究院（National Institutes of Health）多项SBIR资助。